Coxarthrosis; PrimaryNCT06844162
Pericapsular Nerve Group With Lateral Femoral Cutaneous Nerve Block vs Suprainguinal Fascia Iliaca Block for Analgesia in Total Hip Arthroplasty: A Prospective Comparative Study
An observational study of Coxarthrosis; Primary, run by Hacettepe University at 1 site in Turkey (Türkiye).
Trial summary
Prospective observational cohort comparing analgesic efficacy of suprainguinal fascia iliaca block (SFIB) vs pericapsular nerve group block combined with lateral femoral cutaneous nerve block (PENG+LFCN) in primary total hip arthroplasty under general anesthesia (n=48). Read more about this study
- Who is it for?
- Ages 18 to 90 years
- Conditions the study is for
- Coxarthrosis; Primary
- How many people
- 48 participants
- Where
- 1 siteTurkey (Türkiye)
- Study dates
- 1 Feb 2024to 15 Apr 2024
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 90 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: 48 patients of American Society of Anesthesiologists physical status I-II between the age of 18 to 90 years who were scheduled to undergo primary Total hip arthroplasty with a diagnosis of coxarthrosis
Who may be able to join
- Patients who are scheduled to undergo primary total hip arthroplasty with a diagnosis of coxarthosis
Who cannot join
- Patients who have a history of neuropathy, patients with renal and hepatic insufficiency, patients with known coagulopathy, patients with a history of allergy to local anesthetics, patients with a history of inguinal surgery on the same side and patients with impaired mental status
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Comparison of Postoperative Analgesic Efficacy of Suprainguinal Fascia Iliaca Block (SFIB) and Pericapsular Nerve Group (PENG) Block With Lateral Femoral Cutaneous Nerve (LFCN) Block in Patients Undergoing Total Hip Arthroplasty
Prospective observational cohort comparing analgesic efficacy of suprainguinal fascia iliaca block (SFIB) vs pericapsular nerve group block combined with lateral femoral cutaneous nerve block (PENG+LFCN) in primary total hip arthroplasty under general anesthesia (n=48). Outcomes include VAS pain at rest and with movement at 3, 12, 24, 48 h; morphine use (0-3, 3-12, 12-24, 24-48 h; total 0-48 h); quadriceps strength at 6 and 24 h; physiotherapy participation at 24 and 48 h; and adverse events within 48 h.
Read the detailed description
Adults undergoing primary posterolateral THA under general anesthesia were included if they received either SFIB or PENG+LFCN. Pain (VAS at rest and with 45° passive flexion) was recorded at 3, 12, 24, and 48 h. Morphine via PCA was recorded for 0-3, 3-12, 12-24, and 24-48 h, with a 0-48 h total. Quadriceps strength (0-2 scale) was assessed at 6 and 24 h; physiotherapy participation at 24 and 48 h; opioid- or block-related adverse events through 48 h.
- Conditions
- Coxarthrosis; Primary
- Keywords
- Suprainguinal fascia iliaca block, PENG block, Lateral femoral cutaneous nerve block, Postoperative analgesia
- Medical subject headings
- Osteoarthritis, Hip
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| SFIB | Patients undergoing THA who received ultrasound-guided SFIB with 0.25% bupivacaine 40 mL under the fascia iliaca with cranial spread. | |
| PENG | Patients undergoing THA who received ultrasound-guided PENG (0.5% bupivacaine 15 mL) at the iliopubic eminence plus LFCN block (0.5% bupivacaine 5 mL) distal to the inguinal ligament. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Visual Analogue Scale scores
Postoperative Visual Analogue Scale scores ( Minimum of 0 and maximum of 10 with higher scores indicative of more severe pain) will be measured at rest and 45 degrees passive flexion at 3, 12, 24 and 48th hours postoperatively
Measured: In the 48 hours following surgery
Secondary outcomes (3)
Opioid consumption
Opioid consumption during 0-3,12-24, 24-48 hours and cumulative opioid consumption at 48h will be recorded following surgery
Measured: In the 48 hours following surgery
Quadriceps weakness
Quadriceps weakness will be assessed at 6 and 24th hours after surgery. The patient will be asked to extend the knee with the hip flexed at 45 degrees. Quadriceps strength will be graded according to the following: Grade 0: No extension, Grade 1: Extension against gravity but not against resistance, Grade 2: Extension against gravity and resistance.
Measured: In the 48 hours following surgery
Ability to perform physiotherapy
Ability to perform physiotherapy and whether the inability to perform physiotherapy was due to pain or motor weakness will be recorded by the physiotherapist at 24 and 48 hours after surgery
Measured: In the 48 hours following surgery
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted25 Feb 2025
- Study start1 Feb 2024
- Primary completion15 Apr 2024
- Study completion15 Apr 2024
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Coxarthrosis; PrimaryStudies of the same condition, open and under way.
- More trials run by Hacettepe UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 48 participants (actual)
Sponsor and investigators
- Lead sponsor
- Hacettepe University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Güneş Çelebioğlu, Hacettepe University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06844162
- Sponsor's protocol ID
- KA-22088
- Status last verified
- Aug 2025
- First submitted
- 19 Feb 2025
- Last updated
- 26 Aug 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes
Publications
Celebioglu G, Debbag S, Akca B, Saricaoglu F. Pericapsular nerve group with lateral femoral cutaneous nerve block vs. suprainguinal fascia iliaca block for analgesia in total hip arthroplasty: a prospective comparative study. BMC Anesthesiol. 2026 Apr 27;26(1):352. doi: 10.1186/s12871-026-03868-y.
PubMed 42045824
Study at a glance
From the registry record, last updated by the sponsor on 26 Aug 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Comparison of Postoperative Analgesic Efficacy of Suprainguinal Fascia Iliaca Block (SFIB) and Pericapsular Nerve Group (PENG) Block With Lateral Femoral Cutaneous Nerve (LFCN) Block in Patients Undergoing Total Hip Arthroplasty
- ClinicalTrials.gov ID
- NCT06844162
- Acronym / sponsor ID
- KA-22088
- Conditions
- Coxarthrosis; Primary
- Keywords
- Suprainguinal fascia iliaca block, PENG block, Lateral femoral cutaneous nerve block, Postoperative analgesia
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 48 participants (actual)
- Lead sponsor
- Hacettepe UniversityUniversity, hospital or other
- Study start
- 1 Feb 2024 (actual)
- Primary completion
- 15 Apr 2024 (actual)
- Study completion
- 15 Apr 2024 (actual)
- First posted
- 25 Feb 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Prospective observational cohort comparing analgesic efficacy of suprainguinal fascia iliaca block (SFIB) vs pericapsular nerve group block combined with lateral femoral cutaneous nerve block (PENG+LFCN) in primary total hip arthroplasty under general anesthesia (n=48). Outcomes include VAS pain at rest and with movement at 3, 12, 24, 48 h; morphine use (0-3, 3-12, 12-24, 24-48 h; total 0-48 h); quadriceps strength at 6 and 24 h; physiotherapy participation at 24 and 48 h; and adverse events within 48 h.
Detailed description
Adults undergoing primary posterolateral THA under general anesthesia were included if they received either SFIB or PENG+LFCN. Pain (VAS at rest and with 45° passive flexion) was recorded at 3, 12, 24, and 48 h. Morphine via PCA was recorded for 0-3, 3-12, 12-24, and 24-48 h, with a 0-48 h total. Quadriceps strength (0-2 scale) was assessed at 6 and 24 h; physiotherapy participation at 24 and 48 h; opioid- or block-related adverse events through 48 h.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| SFIB | – | –Patients undergoing THA who received ultrasound-guided SFIB with 0.25% bupivacaine 40 mL under the fascia iliaca with cranial spread. |
| PENG | – | –Patients undergoing THA who received ultrasound-guided PENG (0.5% bupivacaine 15 mL) at the iliopubic eminence plus LFCN block (0.5% bupivacaine 5 mL) distal to the inguinal ligament. |
Who may qualify
- Ages
- 18 to 90 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- 48 patients of American Society of Anesthesiologists physical status I-II between the age of 18 to 90 years who were scheduled to undergo primary Total hip arthroplasty with a diagnosis of coxarthrosis
Key inclusion criteria (1 listed)
- Patients who are scheduled to undergo primary total hip arthroplasty with a diagnosis of coxarthosis
Key exclusion criteria (1 listed)
- Patients who have a history of neuropathy, patients with renal and hepatic insufficiency, patients with known coagulopathy, patients with a history of allergy to local anesthetics, patients with a history of inguinal surgery on the same side and patients with impaired mental status
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Visual Analogue Scale scores
Time frame: In the 48 hours following surgery
Postoperative Visual Analogue Scale scores ( Minimum of 0 and maximum of 10 with higher scores indicative of more severe pain) will be measured at rest and 45 degrees passive flexion at 3, 12, 24 and 48th hours postoperatively
3 secondary outcomes
Opioid consumption
Time frame: In the 48 hours following surgery
Quadriceps weakness
Time frame: In the 48 hours following surgery
Ability to perform physiotherapy
Time frame: In the 48 hours following surgery
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 26 Aug 2025.
- Derived from this study: PubMed 42045824Celebioglu G, Debbag S, Akca B, Saricaoglu F. Pericapsular nerve group with lateral femoral cutaneous nerve block vs. suprainguinal fascia iliaca block for analgesia in total hip arthroplasty: a prospective comparative study. BMC Anesthesiol. 2026 Apr 27;26(1):352. doi: 10.1186/s12871-026-03868-y.
- Individual participant dataSharing planned: Yes
Related trials for Coxarthrosis; Primary
Not yet recruiting
DEXA Bone Density Analysis of the CoreHip® Prosthesis System
Primary Osteoarthritis, Cartilage Degeneration
Recruiting
Hip Replacement System (HRS-P) in Primary Total Hip Arthroplasty
Osteoarthritis of Hip
Recruiting
Safety and Effectiveness of the HIT Reverse HRS
Degenerative Joint Disease, Osteoarthritis, Hip
Recruiting
Clinical Outcomes of Primary Cementless Total Hip Arthroplasty Using the Collarless Actis Stem
Osteoarthritis, Hip, Femur Head Necrosis
Not yet recruiting
Prospective Catalystem CT-RSA
Hip Osteoarthritis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Coxarthrosis; Primary, run by Hacettepe University at 1 site in Turkey (Türkiye).
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 26 Aug 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Turkey (Türkiye). Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Visual Analogue Scale scores (time frame: In the 48 hours following surgery). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT06844162, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 26 Aug 2025.